Targeting treatment options for castration-resistant prostate cancer

Am J Clin Exp Urol. 2021 Feb 15;9(1):101-120. eCollection 2021.ABSTRACTProstate cancer (PCa) is the most commonly diagnosed solid tumor and the second leading cause of cancer-related deaths in U.S. men in 2020. Androgen-deprivation therapy (ADT) is the standard of care for metastatic PCa. Unfortunately, PCa relapse often occurs one to two years after initiation of ADT, resulting in the development of castration-resistant PCa (CRPCa), a lethal disease. While several anticancer agents such as docetaxel, abiraterone acetate, and enzalutamide are currently utilized to extend a patient's life after development of CRPCa, patients will eventually succumb to the disease. Hence, while targeting androgen signaling and utilization of docetaxel remain the most crucial agents for many of these combinations, many studies are attempting to exploit other vulnerabilities of PCa cells, such as inhibition of key survival proteins, anti-angiogenesis agents, and immunotherapies. This review will focus on discussing recent advances on targeting therapy. Several novel small molecules will also be discussed.PMID:33816699 | PMC:PMC8012826

Source: Clinical Prostate Cancer - April 5, 2021 Category: Cancer & Oncology Authors: Dannah R Miller Matthew A Ingersoll Benjamin A Teply Ming-Fong Lin Source Type: research